Showing 461 - 480 results of 542 for search '"Sir"', query time: 0.05s Refine Results
  1. 461

    Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases by Erica S. Tsang, Jonathan M. Loree, Janine M. Davies, Sharlene Gill, David Liu, Stephen Ho, Daniel J. Renouf, Howard J. Lim, Hagen F. Kennecke

    Published 2020-01-01
    “…The median Y-90 dose was 2.2 GBq (range 0.8–3.6), as SIR-spheres (69%) or TheraSpheres (29%). Median time to Y-90 from diagnosis of metastases measured 1.54 years. 88% received segmental Y-90, with 1 (69%), 2 (29%), and 3 (2%) treatments. …”
    Get full text
    Article
  2. 462
  3. 463
  4. 464
  5. 465
  6. 466

    Harnessing Non-Antibiotic Strategies to Counter Multidrug-Resistant Clinical Pathogens with Special Reference to Antimicrobial Peptides and Their Coatings by Shyam Kumar Mishra, Tanzina Akter, Umme Laila Urmi, George Enninful, Manjulatha Sara, Jiawei Shen, Dittu Suresh, Liangjun Zheng, Elias Shiferaw Mekonen, Binod Rayamajhee, Francesco M. Labricciosa, Massimo Sartelli, Mark Willcox

    Published 2025-01-01
    “…Antimicrobial resistance is a critical global challenge in the 21st century, validating Sir Alexander Fleming’s warning about the misuse of antibiotics leading to resistant microbes. …”
    Get full text
    Article
  7. 467
  8. 468
  9. 469
  10. 470
  11. 471
  12. 472

    A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients by Wang M, Yue X, Ding Y, Cai Z, Xiao H, Huang H, He J

    Published 2025-02-01
    “…Mowang Wang,1– 4,* Xiaoyan Yue,5,* Yingying Ding,5,* Zhen Cai,1,4 Haowen Xiao,5 He Huang,1– 4 Jingsong He1,4 1Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People’s Republic of China; 2Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, Zhejiang Province, People’s Republic of China; 3Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang Province, People’s Republic of China; 4Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang Province, People’s Republic of China; 5Department of Hematology and Cell Therapy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People’s Republic of China*These authors contributed equally to this workCorrespondence: He Huang; Jingsong He, Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang Province, 310006, People’s Republic of China, Email huanghe@zju.edu.cn; hejingsong@zju.edu.cnPurpose: The growth and survival of multiple myeloma (MM) cells depend heavily on bone marrow microenvironment, where inflammation emerges as a significant feature and is commonly associated with unfavorable prognosis in MM. …”
    Get full text
    Article
  13. 473
  14. 474
  15. 475
  16. 476
  17. 477
  18. 478
  19. 479
  20. 480